SenePlex+: The Clinical Findings

Distributors who cite the real study data build trust that lasts — and protect themselves and SeneGence from compliance risk.

Anyone can say a product "works." What sets SenePlex+ apart is that its key claims are backed by independent, third-party clinical studies — real labs, real subjects, real measurements.

When you cite the actual numbers with their footnotes instead of marketing memory, you're more persuasive AND more protected. Vague hype is forgettable; a specific, sourced number is what makes a client trust you enough to buy.

SeneGence is a direct-sales company, which means the FTC holds the company (and, by extension, its field) responsible for claims distributors make in public — on social media, at parties, in DMs. Two things make precision essential: (1) claims get repeated and reposted verbatim, so any embellishment compounds across thousands of distributors; (2) a bare, unsourced percentage is exactly the pattern FTC enforcement targets.

This packet is built entirely from the homogenized, verified study data — not from older marketing copy, some of which includes numbers the verified studies don't support (see Card 4). Treat every stat here as the current, correct version.

SenePlex+ was tested in two independent clinical studies — not just "trust us," real labs, real subjects, real numbers.

Study 1 (cell-renewal "hero" study): Essex Testing Clinic, 33 subjects, 20-day dansyl-chloride surface-renewal study — treated site vs. an untreated control site on the same subjects.

Study 2 (everyday-results study): Validated Claim Support LLC, 32 subjects, 8-week regimen study (Cleanser + Day + Evening Moisturizer, all with SenePlex+), dermatologist-supervised, measuring hydration, firmness, tone and texture against each subject's own baseline.

Study 1 detail: Essex Testing Clinic (ETC), Panel 22107, Verona NJ. 34 subjects enrolled / 33 completed, dates 21 Mar–11 Apr 2022. Test article: Evening Moisturizer Normal to Dry (SGF21090-01), which contains SenePlex+. Method: dansyl chloride stains the skin's surface cells; as those cells shed and renew, the stain fades — faster fade means faster surface turnover. Scored by visual clinical evaluation ("time to extinction" = full surface turnover), treated site vs. untreated control site.

Study 2 detail: Validated Claim Support LLC (VCS), Teaneck NJ, Study CS211017 / Protocol PR211017.V02. 34 enrolled / 32 completed, all female, ages 25–70 (mean 54). Medical Investigator: David A. Wrone, M.D. (dermatologist); PI: Anna Hardy. Design: 8-week monadic study, GCP/ICH-compliant — note it was NOT submitted to FDA and no IRB was requested, so avoid implying FDA involvement. Measured instrumentally (Corneometer for hydration, Cutometer for firmness/elasticity, Chromameter for tone, Dermo for collagen-related skin structure) plus expert dermatology grading and self-reported consumer perception, all against each subject's own Week 0 baseline.

Up to 100% greater surface-cell turnover by day 18.

Approved turnover line: "The SenePlex+ Evening Moisturizer showed up to 100% greater surface-cell turnover than untreated skin by day 18."

Hydration (8-week study): "~50% more hydration immediately, ~29% at 8 weeks." Appearance (8-week, expert-graded): "97% saw more radiant skin, 81% firmer-looking, 72% smoother texture, 56% more even tone."

Turnover was measured at multiple timepoints: 49% greater turnover vs. control at Day 13, 80% at Day 16, 94% at Day 17, and 100% at Day 18 — statistically significant vs. control on Days 2–18, mostly p<0.001. Mean time to full surface turnover: 15.5 ± 0.4 days (treated) vs. 18.0 ± 0.4 days (control), p<0.001. The lab's own recommended framing for this result is "improved exfoliation" — a cosmetic, not biological, description.

For hydration (Corneometer, 8-week study, all p<0.001 vs. baseline): +49.99% immediately, +12.5% at Week 2, +12.0% at Week 4, +28.62% at Week 8.

For expert-graded appearance at Week 8 (all statistically significant, p<0.001 to p≤0.012): brightness/radiance 96.88%, visual firmness 80.65%, texture/smoothness 71.88%, tone evenness 56.25%, fine lines/wrinkles appearance 31.25%. Consumer self-report at Week 8 (n=32): 100% felt more moisturized, 100% said tone looked more supple, 100% said texture felt smoother, 96.88% said more luminous, and 96.88% said they would buy the product.

Say the number AND the study line together. Never say "regenerates cells," "boosts collagen," or "FDA approved."

Rule: every stat travels with its footnote (lab, subject count, duration) — a number with no source is unsupported. Say "appearance of," "showed," "clinically shown" — never "heals," "repairs cells," "stimulates collagen," "regenerates," or "treats."

Never say "FDA approved" or "peer-reviewed/published" (dermatologist-supervised ≠ published/FDA-reviewed). Never use retired hydration numbers (118%/105%) — use ~50%/~29%. Never claim collagen or elasticity improved.

Compliance framework: a claim is defensible when it (a) uses a visual/appearance verb, not a biological mechanism verb, and (b) states study context (who ran it, subject count, duration) next to the number, so it can't be screenshotted as a bare stat.

Findings that do NOT support a claim: collagen (Dermo) +0.43% at Week 8, not significant (p=0.416); elasticity (Cutometer R5) worsened −8.62% at Week 8, and this WAS significant (p=0.047) — measurably worse, so no elasticity claim at all. Instrumental tone (Chromameter L-value) was only significant at Week 4 (+5.96%) and reverted by Week 8 (−0.82%) — don't make an instrumental tone claim; the expert-graded tone-evenness number (56.25%) is the supportable one instead.

The "35.7% increase in cell renewal" sometimes seen in older marketing compares this product's ~18-day turnover to a textbook 28-day "average" cycle, not to this study's own control — it must carry that caveat if used; the direct study-vs-control figures (49–100%) are cleaner and preferred. Never blend these numbers with the older, legacy SeneDerm SenePlex study (23.3% renewal, 54.2% hydration, different instruments/era) — cite one study family, never both together.

Show the client the approved line on your phone — footnote included — so the claim can survive a screenshot.

Label your own before/after photos as personal experience or testimonial — never as "the clinical results," since that data came from the lab's own subjects, not yours.

Safe elevator pitch (approved, can be used verbatim): "SenePlex+ is our Orchid Stem Cell complex that speeds your skin's natural surface renewal — independently tested for up to 100% greater surface-cell turnover by day 18 and ~50% more hydration immediately."

When asked deeper questions, you can accurately state: the studies were run by two named independent third parties (Essex Testing Clinic and Validated Claim Support, LLC), and the 8-week study's Medical Investigator was a licensed dermatologist (Dr. David A. Wrone) — so it is accurate to say a dermatologist was involved in supervising the study. It is not accurate to call the results "peer-reviewed" or "published" (no journal publication), and it is not accurate to say "FDA approved" (cosmetics claims of this kind are not FDA-reviewed, and overstating this crosses into unapproved drug-claim territory).

Real labs, real subjects, real numbers: that's why SenePlex+ claims hold up — and why you always keep the footnote attached.

Two independent studies, not marketing claims: a 20-day cell-turnover study showing up to 100% greater surface-cell turnover than untreated skin by day 18, and an 8-week regimen study showing ~50% immediate hydration, ~29% at 8 weeks, and up to 97% of women seeing more radiant skin.

Say the number, name the study, keep them together — every time.

The findings that survive scrutiny, by instrument: surface-cell turnover up to 100% greater than untreated control by day 18 (Essex dansyl-chloride study); hydration by Corneometer +49.99% immediately and +28.62% at Week 8; and dermatologist-graded appearance at Week 8 — radiance 96.88%, visual firmness 80.65%, texture 71.88%, tone evenness 56.25%.

The measures this study did not support, and that must never be claimed: instrumental collagen (Dermo +0.43%, p=0.416, not significant) and elasticity (Cutometer R5 −8.62%, p=0.047 — significantly worse). Instrumental tone (Chromameter) was mixed, so tone rests on expert grading, not the machine. Cite one study family at a time; never blend in the legacy 23.3%/54.2% SeneDerm numbers.